XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 12 - Segment Data
3 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

The following tables set forth our segment information:

 

  

Three Months Ended June 30,

 
  

2024

  

2023

 

Revenues (a):

        

Sterilization and Disinfection Control (b)

 $22,957  $15,927 

Clinical Genomics

  11,404   13,369 

Biopharmaceutical Development

  12,008   9,889 

Calibration Solutions

  11,801   11,460 

Total revenues

 $58,170  $50,645 
         

Gross profit:

        

Sterilization and Disinfection Control (b)

 $15,558  $11,591 

Clinical Genomics

  6,490   6,728 

Biopharmaceutical Development

  7,959   6,433 

Calibration Solutions

  7,242   6,431 

Gross profit

 $37,249  $31,183 
         

Reconciling items:

        

Operating expense

  31,669   31,847 

Operating income (loss)

  5,580   (664)

Nonoperating expense, net

  1,675   273 

Earnings (loss) before income taxes

 $3,905  $(937)

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(b)

Includes post-acquisition GKE results during the three months ended June 30, 2024.

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

 

  

June 30,

  

March 31,

 
  

2024

  

2024

 

Sterilization and Disinfection Control

 $6,465  $7,014 

Clinical Genomics

  12,156   11,813 

Biopharmaceutical Development

  6,255   6,304 

Calibration Solutions

  6,891   7,544 

Total inventories

 $31,767  $32,675